FindTrial
Sign In

Long term effect of definitive chemoradiotherapy on respiratory function tests in patients with locally advanced (non)-small cell lung carcinoma

Long term effect of definitive chemoradiotherapy on respiratory function tests in patients with locally advanced (non)-small cell lung carcinoma - Chemoradiotherapy and lung function changes in (N)SCLC

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53171
Enrollment
40
Registered
2017-04-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(N)SCLC lungcancer

Interventions

(N)SCLC
Chemoradiotherapy
Pulmonary function

Sponsors

HagaZiekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1.* 18 years of age 2.Histologically of cytologically confirmed diagnosis of (N)SCLC 3.Stage II/III non operable disease 4.Treatment with definite concurrent of sequential chemoradiation between November 2010 and November 2015 5.Lung function testing including DLCO measurement pre-treatment is available 6.Signed written informed consent

Exclusion criteria

Exclusion criteria: Not being able to have another lung function test done (due to death or poor condition)

Design outcomes

Primary

MeasureTime frame
Change in FEV1 and DLCO >1 year after treatment with radiotherapy or combination treatment with chemoradiotherap either concurrent or sequential.—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)